Overview

Omalizumab Weight-Based Dosing Efficacy Trial

Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies.
Phase:
PHASE2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Omalizumab